1-2 of 2
Laia Monserrat
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer

Available to Purchase
Flaminia Pedretti, Mohmed Abdalfttah, Benedetta Pellegrino, Francesca Mateo, Paula Martínez-Sanz, Andrea Herencia-Ropero, Andreu Òdena, Pau Clavell-Revelles, Giorgia Casali, Heura Domènech, Laia Monserrat, Dražen Papić, Alba Mas Malavila, Anna Pascual-Reguant, Herena Eixarch, Marta Guzmán, Olga Rodríguez, Judit Grueso, Sara Simonetti, Roberta Fasani, Paolo Nuciforo, Carmen Espejo, Stefan Florian, Miguel Ángel Pujana, Lara Nonell, Joan Seoane, Viia Valge-Archer, Mark J. O’Connor, Juan C. Nieto, Holger Heyn, Judith Balmaña, Alba Llop-Guevara, Violeta Serra
Journal: Cancer Research
Cancer Res (2025) 85 (10): 1888–1908.
https://doi.org/10.1158/0008-5472.CAN-24-2531
Published: 15 May 2025
View articletitled, Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Open the PDF for Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract P5-13-14: Antitumor activity of patritumab deruxtecan (HER3-DXd), a HER3-directed antibody drug conjugate (ADC) across a diverse panel of breast cancer (BC) patient-derived xenografts (PDXs)

Free
Andreu Òdena, Laia Monserrat, Fara Brasó-Maristany, Marta Guzmán, Judit Grueso, Olga Rodríguez, Maurizio Scaltriti, Sarat Chandarlapaty, Yang Qiu, Kumiko Koyama, Mafalda Oliveira, Aleix Prat, Violeta Serra
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P5-13-14.
https://doi.org/10.1158/1538-7445.SABCS21-P5-13-14
Published: 15 February 2022
View articletitled, Abstract P5-13-14: Antitumor activity of patritumab deruxtecan (HER3-DXd), a HER3-directed antibody drug conjugate (ADC) across a diverse panel of breast cancer (BC) patient-derived xenografts (PDXs)